Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 1Recurrence 1Lymphedema 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Cancer Invasive 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Mastectomy × 90 days × Clear all
NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡